Table 2 Primary and secondary outcomes for all measurepoints by group
Baseline (t0) | 3-month follow-up (t1) | 6-month follow-up (t2) | 9-month follow-up (t3) | 12-month follow-up (t4) | ||
|---|---|---|---|---|---|---|
Outcome | Group | M (SD) | M (SD) | M (SD) | M (SD) | M (SD) |
Cardiovascular risk profile (SCORE2) | Intervention control | 9.91 (6.86) 8.77 (5.22) | 9.06 (5.70) 9.15 (4.85) | 8.80 (5.37) 8.72 (4.90) | 7.75 (4.54) 8.52 (4.89) | 7.51 (4.43) 8.65 (4.95) |
LDL-C | Intervention control | 106.79 (67.76) 95.88 (41.05) | 96.90 (49.85) 95.74 (46.59) | 89.98 (45.80) 94.89 (39.86) | 88.31 (48.22) 96.47 (40.83) | 75.23 (39.92) 86.14 (37.85) |
HbA1c | Intervention control | 5.98 (0.77) 5.93 (0.57) | 6.08 (0.98) 5.99 (0.58) | 6.03 (0.82) 6.04 (0.67) | 5.98 (0.72) 6.14 (0.82) | 5.98 (0.77) 6.02 (0.73) |
Systolic blood pressure | Intervention control | 149.00 (23.99) 142.63 (22.46) | 138.51 (18.96) 144.98 (19.77) | 138.33 (19.09) 139.98 (16.03) | 134.38 (16.40) 143.23 (16.79) | 131.68 (15.64) 141.25 (16.75) |
Physical activity | Intervention control | 220.17 (300.45) 245.74 (381.36) | 254.89 (432.15) 249.50 (377.75) | 269.26 (269.32) 235.76 (232.03) | 378.76 (626.23) 281.26 (280.22) | 291.40 (595.00) 169.98 (175.15) |
Medication adherence | Intervention control | 4.32 (1.51) 4.19 (1.39) | 3.82 (1.09) 4.18 (1.31) | 3.83 (1.24) 4.03 (1.27) | 3.74 (1.07) 3.90 (1.14) | 3.74 (1.00) 3.82 (1.01) |
Quality of life (EuroQoL) | Intervention control | 56.69 (25.55) 63.04 (21.30) | 61.72 (22.72) 64.83 (20.29) | 62.29 (23.69) 64.76 (21.03) | 63.28 (22.82) 63.11 (22.20) | 63.59 (22.54) 58.11 (22.54) |
